Overview

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a extension study of CSTI571B1201 study
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Imatinib Mesylate